MX2016007170A - Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). - Google Patents

Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Info

Publication number
MX2016007170A
MX2016007170A MX2016007170A MX2016007170A MX2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A
Authority
MX
Mexico
Prior art keywords
aml
myeloid leukemia
acute myeloid
combination treatment
novel combination
Prior art date
Application number
MX2016007170A
Other languages
English (en)
Other versions
MX370618B (es
Inventor
Higgins Brian
Nichols Gwen
E Packman Kathryn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016007170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016007170A publication Critical patent/MX2016007170A/es
Publication of MX370618B publication Critical patent/MX370618B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un producto farmacéutico que comprende: a) como primer componente un inhibidor de la interacción MDM2-p53, y b) como segundo componente, citarabina, como preparación combinada para la utilización secuencial o simultánea en el tratamiento del cáncer, particularmente de la LMA.
MX2016007170A 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). MX370618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
PCT/EP2014/076063 WO2015082384A1 (en) 2013-12-05 2014-12-01 Novel combination treatment for acute myeloid leukemia (aml)

Publications (2)

Publication Number Publication Date
MX2016007170A true MX2016007170A (es) 2016-09-08
MX370618B MX370618B (es) 2019-12-17

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007170A MX370618B (es) 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI627954B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG11201604504VA (en) * 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20180043835A (ko) * 2015-09-03 2018-04-30 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 매크로사이클 및 이의 용도
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP7163281B2 (ja) * 2016-06-06 2022-10-31 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療
WO2018027477A1 (zh) * 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
JP6890659B2 (ja) 2016-11-15 2021-06-18 ノバルティス アーゲー ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
US20200281925A1 (en) * 2017-03-31 2020-09-10 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
EP4337228A1 (en) * 2021-05-13 2024-03-20 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのｍｄｍ２阻害剤のバイオマーカー
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
SG11201604504VA (en) * 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
SI3077004T1 (sl) 2020-07-31
HRP20200566T1 (hr) 2020-06-26
CL2016001345A1 (es) 2017-04-07
US20200253999A1 (en) 2020-08-13
CN105792847B (zh) 2019-11-08
US9956243B2 (en) 2018-05-01
PE20160591A1 (es) 2016-06-11
HUE049434T2 (hu) 2020-09-28
LT3077004T (lt) 2020-05-11
PT3077004T (pt) 2020-04-16
US20150157603A1 (en) 2015-06-11
PL3077004T3 (pl) 2020-08-10
TWI678204B (zh) 2019-12-01
TWI627954B (zh) 2018-07-01
RS60142B1 (sr) 2020-05-29
AU2014359422A1 (en) 2016-04-28
JP2016539160A (ja) 2016-12-15
SG11201604504VA (en) 2016-07-28
US20220031726A1 (en) 2022-02-03
DK3077004T3 (da) 2020-04-27
TW201526890A (zh) 2015-07-16
ZA201602829B (en) 2017-04-26
CA2926307C (en) 2021-11-16
US20230381215A1 (en) 2023-11-30
WO2015082384A1 (en) 2015-06-11
IL244888A0 (en) 2016-05-31
TW201840310A (zh) 2018-11-16
MA39040A1 (fr) 2018-01-31
JP2018111700A (ja) 2018-07-19
ES2785203T3 (es) 2020-10-06
EP3077004A1 (en) 2016-10-12
US20160303158A1 (en) 2016-10-20
KR101862955B1 (ko) 2018-05-31
HK1222808A1 (zh) 2017-07-14
IL244888B (en) 2020-11-30
JP2021091690A (ja) 2021-06-17
AU2014359422B2 (en) 2020-03-05
BR112016009669A8 (pt) 2020-04-07
JP6297695B2 (ja) 2018-03-20
CN105792847A (zh) 2016-07-20
PH12016500933A1 (en) 2016-06-27
EP3077004B1 (en) 2020-02-19
AR098576A1 (es) 2016-06-01
EA201690785A1 (ru) 2016-10-31
JP6918724B2 (ja) 2021-08-11
CA2926307A1 (en) 2015-06-11
CR20160173A (es) 2016-06-08
MX370618B (es) 2019-12-17
KR20160070190A (ko) 2016-06-17
BR112016009669B1 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
TW201614068A (en) Fucosidase from bacteroides and methods using the same
MX2020009919A (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX370673B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2014177464A3 (en) Inhibitors of nhr2 and/or runx1/eto-tetramerization
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
NZ717192A (en) Anti-inflammatory tripeptides
MX2015016603A (es) Composiciones de corticosteroides.
WO2015027121A3 (en) Cancer treatment
MX356102B (es) Compuestos y métodos para tratar leucemia.
IN2014MU00495A (es)
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
MX2015013736A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemia por deficiencia de hierro.
UA116811C2 (uk) Комплекси агомелатину та сульфонових кислот, спосіб їх одержання та фармацевтичні композиції, що їх містять

Legal Events

Date Code Title Description
FG Grant or registration